Nasus Pharma Ltd (NSRX) Form 6-K — Aug 19, 2026

Nasus Pharma Ltd. (NYSE American: NSRX) announced on August 19, 2026 that Chief Financial Officer Eyal Rubin is resigning to pursue an opportunity outside the life sciences industry, with his departure effective September 18, 2026. The 6-K states the resignation was not related to any disagreement with the company on operations, policies or practices, and Director of Finance Oren Elmaliach has been appointed interim CFO while a successor search proceeds. Elmaliach, a certified public accountant with more than 15 years of financial experience, has been with Nasus since its inception.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.